Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
View Older Stories View More Recent Stories
-
Form 8.3 - [Accesso Technology Group plc] (CGWL)
-
Canaccord Genuity Starts Sprout Social Inc. (SPT) at Buy
-
Canaccord Genuity Starts Bill.com Holdings Inc. (BILL) at Hold
-
Net Asset Value(s)
-
Musk defies skeptics, meets Tesla delivery goal; shares hit record
-
Inventus Mining Announces Private Placement Financing
-
Pre-Open Stock Movers 01/02: (PULM) (SAVA) (WATT) Higher; (DRRX) (SIG) Lower (more...)
-
MJardin Enters into Definitive Agreement for the Sale of its Cheyenne Cultivation Facility
-
Tesla (TSLA) PT Raised to 'Street High' $515 at Canaccord Genuity
-
Canaccord Genuity Downgrades Badger Meter (BMI) to Sell
-
Tesla says will start delivering China-made Model 3s to public on Jan. 7
-
Form 8.3 - Accesso Technology Group plc
-
TransGlobe Energy Corporation Announces an Update to a Significant Shareholder
-
Xebec Announces Closing of $23 Million Bought Deal Public Offering of Common Shares
-
Castle Biosciences (CSTL) PT Raised to $35 at Canaccord Genuity
-
Form 8.3 - Accesso Technology Group plc
-
Viva Gold Closes First Tranche of Private Placement
-
TransGlobe Energy Corporation Announces Director/PDMR Shareholding
-
Siyata Mobile Closes Private Placement of CDN$7,866,000 in Unsecured Convertible Debentures
-
Canaccord Genuity Downgrades AquaVenture Holdings (WAAS) to Hold
-
TDb Split Corp. Completes Overnight Offering of $35,643,935
-
MRF 2020 Resource Limited Partnership Initial Public Offering – Maximum $50,000,000
-
Neoleukin Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Neoleukin Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Form 8.3 - [Accesso Technology Group plc] (HH Ltd)
-
Horizonte Updates on Its Community Engagement and CSR for the Local Communities Surrounding the Araguaia Nickel Project
-
Aptose Announces Closing of Public Offering of Common Shares
-
Dividend Declaration
-
Annual Financial Report
-
Final Results
-
Form 8.3 - [Accesso Technology Group plc] (HH Ltd)
-
Canaccord Genuity Starts Unisys (UIS) at Hold
-
TransGlobe Energy Corporation Announces an Operations Update
-
Luminex Closes C$10.0 Million Private Placement Led by Ross J. Beaty
-
Canaccord Genuity Downgrades Codan Limited (CDA:AU) (CODAF) to Hold
-
Canaccord Genuity Upgrades InterRent Real Estate Investment Trust (IIP:CN) (IIPZF) to Buy
-
Canaccord Genuity Downgrades StorageVault Canada (SVI:CN) (SVAUF) to Hold
-
Canaccord Genuity Downgrades Brookfield Property Partners L.P. (BPY) to Hold
-
Form 8.3 - [Accesso Technology Group plc] (CGWL)
-
Canaccord Genuity Starts STMicroelectronics (STM) at Buy
-
Canaccord Genuity Downgrades Patriot One Technologies (PAT:CN) (PTOTF) to Hold
-
Neoleukin Therapeutics (NLTX) Prices 8.925M Share Offering at $8.40/Sh
-
Canaccord Genuity Starts II-VI, Inc. (IIVI) at Buy
-
Neoleukin Therapeutics Announces Pricing of $75.0 Million Public Offering
-
Neoleukin Therapeutics Announces Pricing of $75.0 Million Public Offering
-
Boeing 737 MAX freeze divides suppliers into haves and have-nots
-
Neoleukin Therapeutics (NLTX) Announces Proposed $50M Public Offering of Common Stock
-
Neoleukin Therapeutics Announces Proposed Public Offering of Common Stock
-
Neoleukin Therapeutics Announces Proposed Public Offering of Common Stock
-
Powering Precision Health Summit Convenes the World’s Most Renowned Scientific Innovators Advancing Biomarker Technologies

